Bolus alba mit und ohne Gentiana lutea versus Protonenpumpenhemmer-Therapie bei nichterosiver Gastritis – Eine retrospektive Analyse

Wolf Köster, Christian Scheffer
Article-ID: DMS-21613-DE
DOI: https://doi.org/10.14271/DMS-21613-DE

  • Login
  • Get Access
  • Export Citation

Das Krankheitsbild einer Gastritis stellt eine Volkskrankheit dar. Zur Behandlung werden üblicherweise H2-Blocker/Protonenpumpeninhibitoren eingesetzt. Ziel dieser retrospektiven Untersuchung war die Erhebung des Verlaufs bei stationären Patient:innen mit Gastritis unter einer Bolus-alba-Therapie (Ba-Gl = Bolus alba +/- Gentiana lutea). Es wurden die Krankheitsverläufe aller Patient:innen des Jahres 2018 mit histologisch nachgewiesener nichterosiver Gastritis überprüft, die eine Bolus-alba-Therapie erhielten. Die Patient:innen wurden bezüglich ihrer Medikamenteneinnahme verglichen. Die Ergebnisse zeigen, dass bei Patient:innen mit nichterosiver Gastritis eine Behandlung mit Ba-Gl vergleichbar wirksam sein kann wie eine Therapie mit Protonenpumpeninhibitoren.

Bolus alba with and without Gentiana lutea versus proton pump inhibitor therapy for nonerosive gastritis – A retrospective analysis

The clinical picture of gastritis is a widespread disease. H2 blockers/proton pump inhibitors are usually used for treatment. The aim of this retrospective study was to assess the course of gastritis in inpatients receiving bolus alba therapy (Ba-Gl = Bolus alba with and without Gentiana lutea). The disease courses of all patients with histologically proven nonerosive gastritis who received bolus alba therapy in 2018 were reviewed. The patients were compared with regard to their medication intake. The results show that in patients with nonerosive gastritis, treatment with Ba-Gl can be comparably effective to therapy with proton pump inhibitors.

1 Bornemann R, Gaber E. Gastritis, Magen- und Zwölffingerdarmgeschwüre: Themenheft 55. Berlin: Robert Koch-Institut; 2013. Verfügbar unter https://edoc.rki.de/handle/176904/3242 (09.10.2022).

2 Ärzte verordnen weniger Protonenpumpenhemmer. Deutsches Ärzteblatt; 2017. Verfügbar unter https://www.aerzteblatt.de/nachrichten/87053/Aerzte-verordnen-weniger-Protonenpumpenhemmer (09.10.2022).

3 Imhann F, Vich Vila A, Bonder MJ, et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes 2017;8(4):351–358. DOI: https://doi.org/10.1080/19490976.2017.1284732. [Crossref]

4 Diao X. Antibiotics and proton pump inhibitors suppress the efficacy of immunotherapy against non-small cell lung cancer. Thoracic Cancer 2020;11(7):1763–1764. DOI: https://doi.org/10.1111/1759-7714.13470. [Crossref]

5 Chalabi M, Cardona A, Nagarkar DR, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Annals of Oncology 2020;31(4):525–531. DOI: https://doi.org/10.1016/j.annonc.2020.01.006. [Crossref]

6 Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. New England Journal of Medicine 2010;363(20):1909–1917. DOI: https://doi.org/10.1056/NEJMoa1007 964.

7 van Leeuwen RWF, Peric R, Hussaarts KGAM, et al. Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-Cell lung cancer. Journal of Clinical Oncology 2016;34(12):1309–1314. DOI: https://doi.org/10.1200/JCO.2015.65.2560. [Crossref]

8 Indikationen, Nutzen und Risiken von Protonenpumpeninhibitoren. Deutsches Ärzteblatt; 2016. Verfügbar unter https://www.aerzteblatt.de/archiv/180624/Indikationen-Nutzen-und-Risiken-von-Protonenpumpeninhibitoren (09.10.2022).

9 Bouwknegt M, van Pelt W, Kubbinga ME, et al. Potential association between the recent increase in campylobacteriosis incidence in the Netherlands and proton-pump inhibitor use – an ecological study. Euro Surveillance 2014;19(32):20873. DOI: https://doi.org/10.2807/1560-7917.es2014.19.32.20873. [Crossref]

10 Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. American Journal of Gastroenterology 2007;102(9):2047–2056.

11 Dial S, Delaney JAC, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294(23):2989–2995. DOI: https://doi.org/10.1001/jama.294.23.2989. [Crossref]

12 Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. American Journal of Gastroenterology 2012;107(7):1001–1010. DOI: https://doi.org/10.1038/ajg.2012.179. [Crossref]

13 von Rahden BHA, Scheurlen M, Filser J, et al. Neu erkannte Nebenwirkungen von Protonenpumpeninhibitoren. Die Chirurgie 2012;83(1):38–44.

14 Andrès E, Noel E, Abdelghani MB. Vitamin B(12) deficiency associated with chronic acid suppression therapy. Annals of Pharmacotherapy 2003;37(11):1730. DOI: https://doi.org/10.1345/aph.1D189. [Crossref]

15 Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Archives of Internal Medicine 2010;170(9):765–771. DOI: https://doi.org/10.1001/archinternmed.2010.94. [Crossref]

16 Härmark L, van der Wiel HE, de Groot MCH, et al. Proton pump inhibitor-induced acute interstitial nephritis. British Journal of Clinical Pharmacology 2007;64(6):819–823. DOI: https://doi.org/10.1111/j.1365-2125.2007.02927.x. [Crossref]

17 Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009;301(20):2120–2128. DOI: https://doi.org/10.1001/jama.2009.722. [Crossref]

18 Kwok CS, Yeong JKY, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone 2011;48(4):768–776. DOI: https://doi.org/10.1016/j.bone.2010.12.015. [Crossref]

19 Laheij RJF, Sturkenboom MCJM, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acidsuppressive drugs. JAMA 2004;292(16):1955–1960. DOI: https://doi.org/10.1001/jama.292.16.1955. [Crossref]

20 Ray S, Delaney M, Muller AF. Proton pump inhibitors and acute interstitial nephritis. BMJ 2010;341:c4412. DOI: https://doi.org/10.1136/bmj.c4412. [Crossref]

21 Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for communityacquired pneumonia. Annals of Internal Medicine 2008;149(6):391–398. DOI: https://doi.org/10.7326/0003-4819-149-6-200809160-00005. [Crossref]

22 Sierra F, Suarez M, Rey M, et al. Systematic review: Proton pump inhibitor-associated acute interstitial nephritis. Alimentary Pharmacology and Therapeutics 2007;26(4):545–553. DOI: https://doi.org/10.1111/j.1365-2036.2007.03407.x. [Crossref]

23 Simpson IJ, Marshall MR, Pilmore H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology 2006;11(5):381–385. DOI: https://doi.org/10.1111/j.1440-1797.2006.00651.x. [Crossref]

24 Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcified Tissue International 2006;79(2):76–83. DOI: https://doi.org/10.1007/s00223-006-0021-7. [Crossref]

25 Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296(24):2947–2953. DOI: https://doi.org/10.1001/jama.296.24.2947. [Crossref]

26 Fossmark R, Johnsen G, Johanessen E, et al. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Alimentary Pharmacology and Therapeutics 2005;21(2):149–154. DOI: https://doi.org/10.1111/j.1365-2036.2004.02271.x. [Crossref]

27 Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Annals of Internals Medicine 2010;153(6):378–386. DOI: https://doi.org/10.7326/0003-4819-153-6-201009210-00005. [Crossref]

28 McColl KEL, Gillen D. Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat. Gastroenterology 2009;137(1):20–22. DOI: https://doi.org/10.1053/j.gastro.2009.05.015. [Crossref]

29 Reimer C, Søndergaard B, Hilsted L, et al. Proton-pump inhibitor therapy induces acidrelated symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009;137(1):80–87. DOI: https://doi.org/10.1053/j.gastro.2009.03.058. [Crossref]

30 Chronische Gastritis – AMBOSS. Verfügbar unter https://www.amboss.com/de/wissen/Chronische_Gastritis (09.10.2022).

31 Vademecum Anthroposophische Arzneimittel: Bd. 1. 4. Aufl. München: Verlag der Gesellschaft Anthroposophischer Ärztinnen und Ärzte in Deutschland; 2017.

32 Girke M. Innere Medizin: Grundlagen und therapeutische Konzepte der Anthroposophischen Medizin. 3. Aufl. Berlin: Salumed Verlag; 2020.

33 Vogel HH. Wege der Heilmittelfindung: am Beispiel der WALA Heilmittel-Kompositionen. Berlin: Salumed Verlag; 2019.

34 Wellhausen F, Mocka S, Meyer U. Anwendungsbeobachtung WALA Bolus alba comp. Pulver. Der Merkurstab 2009;62(1):61–64. DOI: https://doi.org/10.14271/DMS-19377-DE.

35 Talley NJ, Verlinden M, Jones M. Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form. Alimentary Pharmacology and Therapeutics 2001;15(2):207–216. DOI: https://doi.org/10.1046/j.1365-2036.2001.00900.x. [Crossref]

Merkurstab Newsletter
Latest content with links to all articles.
Free of charge. Without obligation.
Open access to selected articles.
Sign up


J O B   M A R K E T

PRAXIS DR. WEICHERT, KEMPTEN/ALLGÄU
Weiterbildungsassistent oder
Facharzt (m/w/d)
für Allgemeinmedizin 

More details

PRAXIS FÜR ALLGEMEIN- UND FAMILIENMEDIZIN, FILDERSTADT
Facharzt oder WB-Assistenzarzt (m/w/d)
Innere/Allgemeine Medizin

More details

PARACELSUS-KRANKENHAUS,
BAD LIEBENZELL-UNTERLENGENHARDT
Arzt in Weiterbildung (m/w/d)
Innere Medizin/Allgemeinmedizin
More details

KANTONSSPITAL AARAU/SCHWEIZ
Assistenzarzt/Oberarzt (m/w/d)
Integrative Medizin
More details

PRAXIS KIKOMED, AARAU/SCHWEIZ
Facharzt für Kinder- und Jugendmedizin (m/w/d)
Facharzt für Allgemeine Innere Medizin (m/w/d)

More details